A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

Inclusion criteria

• Age 18-75 years old (including both ends), female.
• Pathologically confirmed locally recurrent unresectable or metastatic triple-negative breast cancer.
• Expected survival ≥ 12 weeks.
• Have adequate renal and hepatic function.
• Patients voluntarily joined the study and signed the informed consent.

Exclusion criteria

• Patients with active central nervous system (CNS) metastases who have not undergone surgery or radiotherapy.
• Have other malignancies within the past 5 years.
• Presence with uncontrollable third space effusion.
• Have undergone other anti-tumor treatment within 4 weeks before the first dose.
• A history of immunodeficiency.
• Clinically significant cardiovascular diseases.
• Known or suspected interstitial lung disease.
• Known hereditary or acquired bleeding tendency.
• Toxicities from prior anti-tumor therapy that have not recovered to ≤ Grade 1.
• Known hypersensitivity to any of the study drugs or their excipients, or a history of allergy to humanized monoclonal antibody products.
• Presence of other severe physical or mental disorders or clinically significant laboratory abnormalities.